Clinical Trial Update: Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating interleukin-12 and interleukin-2 in patients with refractory or recurrent neuroblastoma; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Neuroblastoma | Phase 1 | Status: TERMINATED